Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Ascentage Pharma Group International (AAPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: AAPG (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 46.69% | Avg. Invested days 90 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.35B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1 | 52 Weeks Range 16.50 - 40.81 | Updated Date 05/15/2025 |
52 Weeks Range 16.50 - 40.81 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Earnings Date
Report Date 2025-07-03 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -39.9% | Operating Margin (TTM) 22.82% |
Management Effectiveness
Return on Assets (TTM) -7.14% | Return on Equity (TTM) -52.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1665238458 | Price to Sales(TTM) 7.03 |
Enterprise Value 1665238458 | Price to Sales(TTM) 7.03 | ||
Enterprise Value to Revenue 13.44 | Enterprise Value to EBITDA - | Shares Outstanding 348267008 | Shares Floating 174845965 |
Shares Outstanding 348267008 | Shares Floating 174845965 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Ascentage Pharma Group International
Company Overview
History and Background
Ascentage Pharma Group International is a global biopharmaceutical company focused on developing innovative therapies for cancer, aging-related diseases, and other unmet medical needs. The company was founded in 2009.
Core Business Areas
- Drug Discovery & Development: Focuses on creating and developing novel small molecule drugs for oncology and aging-related diseases.
- Clinical Trials: Conducts clinical trials globally to evaluate the safety and efficacy of its drug candidates.
- Commercialization: Aims to commercialize its approved therapies globally, either independently or through partnerships.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company has a matrix organizational structure to manage drug development programs and commercial activities.
Top Products and Market Share
Key Offerings
- Olverembatinib (HQP1351): A third-generation BCR-ABL inhibitor approved in China for treatment-resistant chronic myeloid leukemia (CML). Competitors: Novartis's Tasigna and Pfizer's Bosulif. Market share data unavailable, primarily China market focused.
- APG-115: A potent and selective MDM2 inhibitor currently in clinical development for various cancers. Competitors: Nutlin-3. Revenue or user data currently unavailable.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. Innovation is crucial for success.
Positioning
Ascentage Pharma aims to become a global leader in innovative cancer therapies, particularly focusing on targeted therapies and kinase inhibitors.
Total Addressable Market (TAM)
The global oncology market is estimated to reach over $500 billion by 2028. Ascentage Pharma is positioning itself to capture a portion of this TAM through its innovative pipeline.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Innovative drug pipeline
- Experienced management team
- Global clinical trial network
Weaknesses
- Limited commercial presence outside China
- Reliance on clinical trial success
- High cash burn rate
- Competition from larger pharmaceutical companies
Opportunities
- Expanding into new markets
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies
- Developing new therapies for unmet medical needs
Threats
- Clinical trial failures
- Regulatory delays
- Competition from generic drugs
- Economic downturns
Competitors and Market Share
Key Competitors
- NVS
- PFE
- BMY
- MRK
Competitive Landscape
Ascentage Pharma faces intense competition from larger, established pharmaceutical companies. Its competitive advantage lies in its innovative pipeline and focus on targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancing its drug pipeline through clinical trials and securing regulatory approvals.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates unavailable.
Recent Initiatives: Focus on expanding clinical trials globally and seeking partnerships for commercialization.
Summary
Ascentage Pharma is a promising biopharmaceutical company with a strong pipeline of innovative cancer therapies. Its R&D capabilities and experienced management team are key strengths. However, it faces challenges related to commercialization, competition, and financial sustainability. Securing partnerships and achieving clinical trial success are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Various News Sources
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data are estimates and may vary. Financial data are based on available information and may not be complete or accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ascentage Pharma Group International
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-01-24 | Co-Founder, Chairman & CEO Dr. Dajun Yang M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 567 | Website https://www.ascentage.cn |
Full time employees 567 | Website https://www.ascentage.cn | ||
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.